About The Company
The company is engaged in medicine business . Dr Reddy's , Ranbaxy and Cipla are some of the market leaders in this segment. The stock has been fancied among the investor for long time in the capital market.
About The Results
The company has posted result for the last quarter with a PAT at Rs.192 crore. The earnings would have been much higher but for the lower earnings from
Overall revenues were up 49% on a YoY at Rs. 1840 crore. EBITDA was up 58%. Net profit was at Rs.192.0 crore as against a net loss of Rs.121.30 crore it posted in Q3FY08. What is commendable is that it posted a net forex loss of Rs 49.3 crore as against a net gain of Rs. 8.7 crore in Q3FY08. The forex loss was mainly on account of fluctuations of Russian Rouble.
Dr Reddy’s launched 10 new products during the quarter and it plans to launch two biologics products during next fiscal in the domestic market. For FY10, the company has projected a flat growth as a lot of its growth depends on the outcome of its tenders in
About The Stock
The stock has been evergreen performer but some pain is yet left and need to be over before fresh buying in this counter.
Disclaimer : I do not have any personal holding in this company.